News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
December, 2023
December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Paolo A. Ascierto: I owe it every day to Giuseppe, to Carla, to Rosina, to Gabriele, to the many who are still part of that 50% who are less lucky
Photo taken from Paolo A. Ascierto/LinkedIn
Oct 31, 2023, 15:37

Paolo A. Ascierto: I owe it every day to Giuseppe, to Carla, to Rosina, to Gabriele, to the many who are still part of that 50% who are less lucky

Quoting Paolo A. Ascierto, Director Department of Melanoma, Cancer Immunotherapy, Development Therapeutics at the National Cancer Institute IRCCS G. Pascale Foundation on LinkedIn:

“Giuseppe was 17 years old, he passed away around Christmas, and who ever forgets that Christmas, it was like losing a son, a brother, a father. Before Giuseppe there was Carla, today she would have been 58 years old. She was Adolfo’s sister, my friend met during the year of service in the Air Force, whose wedding I later witnessed and with whom I spent my life it intersects cyclically, as often happens in ancient feelings. Carla passwd away in 1999. Before that moment she made and gave me a crochet painting which is now in my department, on the first floor of the IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy. Rosina died very young. I tried to save her with the vaccine, the Cancer vax, for which we had so much hope. At the time I thought it could prove to be a cure that could, if not completely eradicate, at least block the tumor. Rosina always brought me tagliatelle when she came to visit and before dying her brother confided to me one day that she had had a thought for me even on her deathbed. Every time I eat tagliatelle I think of her. I still can’t mention Gabriele without my voice getting caught in my throat. He died in 2020 for a metastatic melanoma. He was 17 years old and he passed away within a few weeks. Gabriele is part of that 50 percent of patients that we still cannot save and for whom science can and must still do a lot.

To Gabriele, but more ultimately to all my patients who passed away, I dedicate these 30 years of my life at Pascale. It was October 28, 1993 when I was hired as medical director in this Institute. They have been 30 intense years. Thirty years of bitter defeats, but also of great personal and above all professional satisfaction, of travel around the world in desperate search of that drug which today saves, yes, I can say with pride “it saves”, the lives of 50% of patients suffering from melanoma. A percentage that still cannot be enough for us and for which I continue to work, together with my collaborators, with the same enthusiasm as when I joined Pascale. I owe it every day to Giuseppe, to Carla, to Rosina, to Gabriele, to the many who are still part of that 50% who are less lucky.”

Source: Paolo A. Ascierto/LinkedIn.

cancer IRCCS OncoDaily Oncology Paolo A. Ascierto
Blog
Dec 10, 2023, 19:32
Tomain Murphy: We celebrated a colossal milestone with the delivery of the proton accelerator
Blog
Dec 10, 2023, 19:19
Wafik S. El-Deiry: I am super excited to be able to share guest editorial in The Cancer Letter with the vision for the Worldwide Innovative Network WIN Consortium in cancer personalized medicine
Blog
Dec 10, 2023, 19:10
Margaret Foti: We are proud to work with our partners to help this critical symposium grow and thrive
Blog
Dec 10, 2023, 18:16
Jérôme Salomon: World Health Organization is also releasing a technical manual on alcohol tax policy and administration
Insight
Dec 10, 2023, 18:12
The Cancer Research Interns (CRI) Summer Program is now accepting applications! - Train at NCI
Insight
Dec 10, 2023, 18:08
Apply for the Basic Research in Cancer Health Disparities Program - NCI Center to Reduce Cancer Health Disparities (CRCHD)
Blog
Dec 10, 2023, 18:07
Nathan Vardi: I traveled down to Maryland and spent the day at the FDA
Insight
Dec 10, 2023, 18:01
Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward
Blog
Dec 10, 2023, 17:54
Christian Rutzer: Roche and Novartis - Basel's Research and Innovation Powerhouses
Blog
Dec 10, 2023, 17:48
Nick Vitanza: It's been a dream to bring better treatments to kids with DIPG and CNS tumors
Career
Dec 10, 2023, 17:39
Dr. Salami is the winner of the American Urological Association’s prestigious Gold Cystoscope Award - YUO
Blog
Dec 10, 2023, 17:32
Wafik S. El-Deiry: I wore my chemistry tie today in honor of your visit to Providence and Brown University
Insight
Positive
Societies
Career